June: Announced positive results from Phase IIa trial in 200 adult participants. Both primary and secondary endpoints met.
February: Positive interim safety results announced
2010
November: Raised $1.25m using Yorkville SEDA
October: Commenced immunizations in first Phase II clinical trial
August: Received Ethics ('Helsinki') Committee Approvals for the Initiation of first Phase II Clinical Trial for Universal Influenza Vaccine
July: Received Frost & Sullivan '2010 European Influenza Vaccines Technology Innovation Award'
June: Received third annual consecutive grant from Israeli Office of Chief Scientist for $1 million towards the development of the Universal Influenza Vaccine
April: Announced final safety and immunogenicity results from second Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains
March: Announced positive interim safety results from the second Phase I/II trial in 60 elderly participants - the Multimeric-001 was found to be safe and well tolerated
February: Signed a term sheet with Yorkville Advisers for the provision of a standby equity facility of up to $7m over three years
2009
December: Raised $5.3m in a secondary offering on the Tel Aviv Stock Exchange
December: Announced immunogenicity results from first Phase I/II trial - Multimeric-001 successfully activates both humoral and cellular arms of the immune system, stimulating responses against both Type A and B Influenza strains
August: Reported initial safety results from first Phase I/II trial - no significant adverse events found
June: Initiated Phase I/II trial in 63 healthy adult volunteers
February: Concluded GLP toxicology study
2008
November: Commenced a repeated (3 dose) GLP toxicology study using the maximal human dose
July: Pre-IND Meeting. BiondVax presented its pre- and clinical plans for the Multimeric-001 universal flu vaccine to the FDA in a Pre-IND meeting
2007
November: Voluntarily terminated first Phase I trial
October: Avian flu study in collaboration with Israeli Veterinarian Institute
July: Commenced Phase I clinical trial of 1st Generation vaccine
June: IPO on the Tel Aviv Stock Exchange, raising about $3m
2006
Conducted pre-clinical and toxicology studies
Production of 1st Generation vaccine
2005
Company operations begin
Initial fundraising round completed
2004
Initial fundraising round commenced
2003
Signed a license agreement with the Weizmann Institute for the in-licensing to BiondVax of the patent relating to the Peptide-based Vaccine for Influenza
BiondVax Pharmaceuticals Ltd. established as an Israeli company
1988 - 2002
15 years of R&D led by Prof. Ruth Arnon and her team at the Weizmann Institute of Science
Established feasibility of Universal Peptide-based Influenza Vaccine in animals
